Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Dixon_Ed_1000x714_ENV

Edward H. Dixon

Of Counsel

Washington +1 202 662 5541

  • About
  • Representative Matters
  • Credentials
  • About

    Ed Dixon is a member of the firm’s corporate group and is resident in the Washington office.  His practice focuses on the Life Sciences industry.  Ed regularly advises pharmaceutical and biotechnology clients on a full range of transactional matters, including complex licensing and collaboration arrangements, acquisitions and divestitures of pharmaceutical companies and products, marketing and co-promotion agreements, and supply and distribution transactions, including authorized generic distribution agreements. 

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • AstraZeneca in its strategic diabetes alliance with Bristol-Myers Squibb in connection with BMS’s acquisition of Amylin Pharmaceuticals.
    • Eisai in connection with a marketing and supply agreement with Arena Pharmaceuticals, Inc. for the exclusive right to commercialize lorcaserin for obesity and weight management in North and South America.
    • AstraZeneca in connection with its agreement granting Pfizer worldwide rights to sell an OTC version of AstraZeneca’s blockbuster proton pump inhibitor, Nexium. 
    • AstraZeneca in its global collaboration with The Medicines Company to develop and commercialize acute ischemic heart disease compounds.
    • Eli Lilly and Company in supply and distribution arrangements for its radiopharmaceutical PET imaging agent Amyvid™.
    • Eisai in its worldwide collaboration with Epizyme, Inc. to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.

    • AstraZeneca in a worldwide collaboration with Targacept, Inc. to develop and commercialize a late-stage investigational product for major depressive disorder.
    • AstraZeneca in its co-promotion arrangements with Abbott for AstraZeneca's Crestor® and Abbott’s Trilipix®.
    • AstraZeneca in its global collaboration with Bristol-Myers Squibb to develop and commercialize the diabetes drugs Onglyza® and Forxiga®.
    • AstraZeneca in its collaboration with Abbott to develop a combination product containing fenofibrate and AstraZeneca’s statin Crestor®. 
    • Merck in its distribution arrangements for authorized generic versions of Zocor® and Proscar®.

    Areas of Expertise

  • Credentials
    Education
    • University of Michigan, J.D., 1993
        • cum laude
        • Michigan Law Review, Contributing Editor
    • Columbia University, B.A., 1986
        • magna cum laude
        • Phi Beta Kappa
    Bar Admissions
    • District of Columbia
    • Vermont
    Accolades
    • Washington DC Super Lawyers (2014-2015) 
    • Legal 500 US, Patent: Portfolio Management and Licensing (2016) 
    • Legal 500 US, Healthcare: Life Sciences (2013-2014)
    • LMG Life Sciences, "Life Science Star - Finance & Transactional" (2012-2013)

    Areas of Expertise

News and Insights

Events